After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the presentation focused on the Cystic Fibrosis commercial business, potential launch dynamics for Alyftrek and suzetrigine, as well as Casgevy and the company’s “broad and progressing pipeline.” The firm, which continues to view Vertex as “a core large-cap biotech holding” and sees 2025 as focused on launch execution, steady CF growth and continued clinical progress, maintains an Overweight rating on the shares.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $456 from $476 at Morgan Stanley
- Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
- Vertex Pharmaceuticals, Orna Therapeutics announce research collaboration
- Yum, Ralph Lauren upgraded: Wall Street’s top analyst calls
- Top 3 Trending Stocks, According to Analysts – 12/25/2024